A Randomized, Sponsor-Open, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of RO7062931 With Single Ascending Doses in Healthy Volunteers and Multiple Doses and Modified Regimens in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection

Trial Profile

A Randomized, Sponsor-Open, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of RO7062931 With Single Ascending Doses in Healthy Volunteers and Multiple Doses and Modified Regimens in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2018

At a glance

  • Drugs RO 7062931 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 20 Aug 2018 Planned End Date changed from 7 May 2019 to 25 Apr 2019.
    • 20 Aug 2018 Planned primary completion date changed from 7 May 2019 to 25 Apr 2019.
    • 17 Jul 2018 Planned End Date changed from 21 May 2019 to 7 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top